Update on the effects of the sodium pump α1 subunit on human glioblastoma: from the laboratory to the clinic

References

• Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Res. 2017;6:1892.
   PubMedGoogle Scholar
• Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma-an update. Crit Rev Oncol Hematol. 2016;99:389–408.
   PubMed Web of Science ®Google Scholar
• Würth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014;2014:126586.
   PubMedGoogle Scholar
• Cloughesy T. FDA accelerated approval benefits glioblastoma. Lancet Oncol. 2010;11:1120.
   PubMed Web of Science ®Google Scholar
• Rinne ML, Lee EQ, Nayak L, et al. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013;18:137–153.
   PubMed Web of Science ®Google Scholar
• Ye Q, Li Z, Tian J, et al. Identification of a potential receptor that couples ion transport to protein kinase activity. J Biol Chem. 2011;286:6225–6232.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, Roland I, Van Quaquebeke E, et al. The alpha1 subunit of the sodium pump could represent a novel target to combat nonsmall cell lung cancers. J Pathol. 2007;212:170–179.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Z, Xie JX, et al. Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cell. J Biol Chem. 2011;286:32394–32403.
   PubMed Web of Science ®Google Scholar
• Khundmiri SJ, Salyer SA, Farmer B, et al. Structural determinants for the ouabain-stimulated increase in Na-K ATPase activity. Biochim Biophys Acta. 2014;1843:1089–1102.
   PubMed Web of Science ®Google Scholar
• Sottejeau Y, Belliard A, Duran MJ, et al. Critical role of the isoform-specific region in alpha1-Na+/K+-ATPase trafficking and protein kinase C-dependent regulation. Biochemistry. 2010;49:3602–3610.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, Van Quaquebeke E, Delest B, et al. Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta. 2007;1776:32–57.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, de Nève N, Gailly P, et al. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther. 2008;7:1285–1296.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Kiss R. The sodium pump α1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia. 2008;10:198–206.
   PubMed Web of Science ®Google Scholar
• Winnicka K, Bielawski K, Bielawska A, et al. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin a in human MCF-7 and MDA-MB-231 breast cancer cells. Biol Pharm Bull. 2008;31:1131–1140.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Mijatovic T, Kondo Y, et al. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery. 2008;62:211–221.
   PubMed Web of Science ®Google Scholar
• Lan YL, Wang X, Lou JC, et al. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na+/K+-ATPase α1 subunit. Biomed Pharmacother. 2018;103:204–215.
   PubMed Web of Science ®Google Scholar
• Com E, Clavreul A, Lagarrigue M, et al. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J Proteomics. 2012;75:3898–3913.
   PubMed Web of Science ®Google Scholar
• Lan YL, Wang X, Lou JC, et al. Marinobufagenin inhibits glioma growth through sodium pump α1 subunit and ERK signaling-mediated mitochondrial apoptotic pathway. Cancer Med. 2018;7:2034–2047.
   PubMed Web of Science ®Google Scholar
• Eisele G, Weller M. Targeting apoptosis pathways in glioblastoma. Cancer Lett. 2013;332:335–345.
   PubMed Web of Science ®Google Scholar
• Lin BH, Tsai MH, Lii CK, et al. IP3 and calcium signaling involved in the reorganization of the actin cytoskeleton and cell rounding induced by cigarette smoke extract in human endothelial cells. Environ Toxicol. 2016;31:1293–1306.
   PubMed Web of Science ®Google Scholar
• Panayiotidis MI, Bortner CD, Cidlowski JA. On the mechanism of ionic regulation of apoptosis: would the Na+/K+-ATPase please stand up? Acta Physiol (Oxf). 2006;187:205–215.
   PubMed Web of Science ®Google Scholar
• Xie Z, Cai T. Na+-K+–ATPase–mediated signal transduction: from protein interaction to cellular function. Mol Interv. 2003;3:157–168.
   PubMedGoogle Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005;23:2411–2422.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 2007;12:1395–1403.
   PubMed Web of Science ®Google Scholar
• Navarro A, Anand-Apte B, Parat MO. A role for caveolae in cell migration. FASEB J. 2004;18:1801–1811.
   PubMed Web of Science ®Google Scholar
• Tanowitz HB, Machado FS, Avantaggiati ML, et al. An expanded role for caveolin-1 in brain tumors. Cell Cycle. 2013;12:1485–1486.
   PubMed Web of Science ®Google Scholar
• Guruswamy S, Rao CV. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: implications for colon cancer prevention. Int J Oncol. 2009;35:1037–1043.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Duan Q, Xie Z. SH2 ligand-like effects of second cytosolic domain of Na/K-ATPase α1 subunit on src kinase. PLoS One. 2015;10:e0142119.
   PubMed Web of Science ®Google Scholar
• Penniyaynen VA, Kipenko AV, Lopatina EV, et al. Effect of ouabain on growth of skin explants in organotypic culture. Bull Exp Biol Med. 2013;154:419–420.
   PubMed Web of Science ®Google Scholar
• Xianyu M, Petrushanko IY, Klimanova EA, et al. Glutathionylation of the alpha-subunit of Na, K-ATPase from rat heart by oxidized glutathione inhibits the enzyme. Biochemistry (Mosc). 2014;79:158–164.
   PubMed Web of Science ®Google Scholar
• Wansapura AN, Lasko VM, Lingrel JB, et al. Mice expressing ouabain-sensitive alpha1-Na, K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2011;300:H347–H355.
   PubMed Web of Science ®Google Scholar
• Loreaux EL, Kaul B, Lorenz JN, et al. Ouabain-sensitive alpha1 Na, K-ATPase enhances natriuretic reponse to salin load. J Am Soc Nephrol. 2008;19:1947–1954.
   PubMed Web of Science ®Google Scholar
• Magpusao AN, Omolloh G, Johnson J, et al. Cardiac glycoside activities link Na+/K+-ATPase ion-transport to breast cancer cell migration via correlative SAR. ACS Chem Biol. 2015;10:561–569.
   PubMed Web of Science ®Google Scholar
• Barwe SP, Anilkumar G, Moon SY, et al. Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell. 2005;16:1082–1094.
   PubMed Web of Science ®Google Scholar
• Stettner MR, Wang W, Nabors LB, et al. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 2005;65:5535–5543.
   PubMed Web of Science ®Google Scholar
• Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27:533–546.
   PubMed Web of Science ®Google Scholar
• Qin M, Zhang J, Xu C, et al. Knockdown of NIK and IKKβ-Binding Protein (NIBP) reduces colorectal cancer metastasis through down-regulation of the canonical NF-κΒ signaling pathway and suppression of MAPK signaling mediated through ERK and JNK. PLoS One. 2017;12:e0170595.
   PubMed Web of Science ®Google Scholar
• Roy N, Chakraborty S, Paul Chowdhury B, et al. Regulation of PKC mediated signaling by calcium during visceral leishmaniasis. PLoS One. 2014;9:e110843.
   PubMedGoogle Scholar
• Chai W, Zhang J, Zhu Z, et al. Pyocyanin from Pseudomonas induces IL-8 production through the PKC and NF-κB pathways in U937 cells. Mol Med Rep. 2013;8:1404–1410.
   PubMed Web of Science ®Google Scholar
• Li Z, Cai T, Tian J, et al. NaKtide, a Na/K-ATPase-derived peptide src inhibitor, antagonizes ouabain-activated signal transduction in cultured cells. J Biol Chem. 2009;284:21066–21076.
   PubMed Web of Science ®Google Scholar
• Tian J, Cai T, Yuan Z, et al. Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Mol Biol Cell. 2006;17:317–326.
   PubMed Web of Science ®Google Scholar
• Chaves AL, de Lima PO, Soares JM, et al. Effects of digoxin and Na, K-ATPase immunoexpression on human oral squamous carcinomas. Anticancer Res. 2014;34:5397–5403.
   PubMed Web of Science ®Google Scholar
• Liu L, Ivanov AV, Gable ME, et al. Comparative properties of caveolar and noncaveolar preparations of kidney Na+/K+-ATPase. Biochemistry. 2011;50:8664–8673.
   PubMed Web of Science ®Google Scholar
• Gable ME, Abdallah SL, Najjar SM, et al. Digitalis-induced cell signaling by the sodium pump: on the relation of Src to Na+/K+-ATPase. Biochem Biophys Res Commun. 2014;446:1151–1154.
   PubMed Web of Science ®Google Scholar
• Clifford RJ, Kaplan JH. Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS One. 2013;8:e84306.
   PubMed Web of Science ®Google Scholar
• Weigand KM, Swarts HG, Fedosova NU, et al. Na,K-ATPase activity modulates Src activation: a role for ATP/ADP ratio. Biochim Biophys Acta. 2012;1818:1269–1273.
   PubMed Web of Science ®Google Scholar
• Li S, Couet J, Lisanti MP. Src tyrosine kinases, G α subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin: caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996;271:29182–29190.
   PubMed Web of Science ®Google Scholar
• Wojtal KA, De Vries E, Hoekstra D, et al. Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide. Mol Biol Cell. 2006;17:3638–3650.
   PubMed Web of Science ®Google Scholar
• Yosef E, Katz A, Peleg Y, et al. Do src kinase and caveolin interact directly with Na,K-ATPase? J Biol Chem. 2016;291:11736–11750.
   PubMed Web of Science ®Google Scholar
• Lingrel JB, Argüello JM, Van Huysse J, et al. Cation and cardiac glycoside binding sites of the Na, K-ATPase. Ann N Y Acad Sci. 1997;834:194–206.
   PubMed Web of Science ®Google Scholar
• Akimova OA, Tverskoi AM, Smolyaninova LV, et al. Critical role of the α1-Na(+), K(+)-ATPase subunit in insensitivity of rodent cells to cytotoxic action of ouabain. Apoptosis. 2015;20:1200–1210.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234.
   PubMed Web of Science ®Google Scholar
• Hoffmann EK, Lambert IH. Ion channels and transporters in the development of drug resistance in cancer cells. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130109.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Harazono Y, Kho DH, Balan V, et al. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget. 2015;6:19592–19604.
   PubMed Web of Science ®Google Scholar
• Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells–much more complex than expected. Mol Cancer. 2011;10:128.
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54:850–860.
   PubMed Web of Science ®Google Scholar
• Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009;20:175–181.
   PubMed Web of Science ®Google Scholar
• Nakai E, Park K, Yawata T, et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest. 2009;27:901–908.
   PubMed Web of Science ®Google Scholar
• Balik V, Mirossay P, Bohus P, et al. Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol. 2009;29:845–858.
   PubMed Web of Science ®Google Scholar
• Xiao AY, Wang XQ, Yang A, et al. Slight impairment of Na+, K + -ATPase synergistically aggravates ceramide- and beta-amyloid-induced apoptosis in cortical neurons. Brain Res. 2002;955:253–259.
   PubMed Web of Science ®Google Scholar
• Chen D, Song M, Mohamad O, et al. Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells. BMC Cancer. 2014;14:716.
   PubMed Web of Science ®Google Scholar
• Zhou J, Scholes J, Hsieh JT. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev. 2001;20:351–362.
   PubMed Web of Science ®Google Scholar
• Kimura K, Markowski M, Bowen C, et al. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 2001;61:5611–5618.
   PubMed Web of Science ®Google Scholar
• Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res. 2005;65:11230–11235.
   PubMed Web of Science ®Google Scholar
• Mawji IA, Simpson CD, Hurren R, et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst. 2007;99:811–822.
   PubMedGoogle Scholar
• Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65:2378–2386.
   PubMed Web of Science ®Google Scholar
• Douma S, Van Laar T, Zevenhoven J, et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430:1034–1039.
   PubMed Web of Science ®Google Scholar
• Simpson CD, Mawji IA, Anyiwe K, et al. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res. 2009;69:2739–2747.
   PubMed Web of Science ®Google Scholar
• Stenkvist B, Bengtsson E, Dahlqvist B, et al. Cardiac glycosides and breast cancer, revisited. N Engl J Med. 1982;306:484.
   PubMed Web of Science ®Google Scholar
• Alevizopoulos K, Calogeropoulou T, Lang F, et al. Na+/K+ ATPase inhibitors in cancer. Curr Drug Targets. 2014;15:988–1000.
   PubMed Web of Science ®Google Scholar
• Haux J, Klepp O, Spigset O, et al. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer. 2001;1:11.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, Op De Beeck A, Van Quaquebeke E, et al. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther. 2006;5:391–399.
   PubMed Web of Science ®Google Scholar
• Van Quaquebeke E, Simon G, André A, et al. Identification of a novel cardenolide (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem. 2005;48:849–856.
   PubMed Web of Science ®Google Scholar
• Mathieu V, Pirker C, Martin De Lassalle E, et al. The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med. 2009;13:3960–3972.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, Mathieu V, Gaussin JF, et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia. 2006;8:402–412.
   PubMed Web of Science ®Google Scholar
• Juncker T, Cerella C, Teiten MH, et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol. 2011;81:13–23.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, Kiss R. Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways. Planta Med. 2013;79:189–198.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Meng C, Lin J, et al. Ouabain targets the Na+/K+-ATPase α3 isoform to inhibit cancer cell proliferation and induce apoptosis. Oncol Lett. 2017;14:6678–6684.
   PubMed Web of Science ®Google Scholar
• Yatime L, Laursen M, Morth JP, et al. Structural insights into the high affinity binding of cardiotonic steroids to the Na+,K+-ATPase. J Struct Biol. 2011;174:296–306.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Shinoda T, Cornelius F, et al. Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. Proc Natl Acad Sci U S A. 2009;106:13742–13747.
   PubMed Web of Science ®Google Scholar
• Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem. 2010;285:19582–19592.
   PubMed Web of Science ®Google Scholar
• Newman RA, Yang P, Pawlus AD, et al. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8:36–49.
   PubMed Web of Science ®Google Scholar
• de Munari S, Cerri A, Gobbini M, et al. Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds. J Med Chem. 2003;46:3644–3654.
   PubMed Web of Science ®Google Scholar
• Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. J Med Chem. 2008;51:4601–4608.
   PubMed Web of Science ®Google Scholar
• Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. Bioorg Med Chem. 2010;18:4275–4299.
   PubMed Web of Science ®Google Scholar
• Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002;303:592–600.
   PubMed Web of Science ®Google Scholar
• Cove DH, Barker GA. Digoxin and hormone receptors. Lancet. 1979;2:204.
   PubMed Web of Science ®Google Scholar
• Khan H, Metra M, Blair JE, et al. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009;14:277–287.
   PubMed Web of Science ®Google Scholar
• Liu T, Wu C, Weng G, et al. Bufalin inhibits cellular proliferation and cancer stem cell-like phenotypes via upregulation of MiR-203 in glioma. Cell Physiol Biochem. 2017;44:671–681.
   PubMed Web of Science ®Google Scholar
• Wang D, Bi Z. Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. Tumour Biol. 2014;35:4885–4890.
   PubMedGoogle Scholar
• Yan S, Qu X, Xu L, et al. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs. 2014;25:683–689.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lonard DM, Yu Y, et al. Bufalin is a potent small molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014;74:1506–1517.
   PubMed Web of Science ®Google Scholar
• Shen S, Zhang Y, Wang Z, et al. Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int J Biol Sci. 2014;10:212–224.
   PubMed Web of Science ®Google Scholar
• Meng Z, Yang P, Shen Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009;115:5309–5318.
   PubMed Web of Science ®Google Scholar
• Osman MH, Farrag E, Selim M, et al. Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies. PLoS One. 2017;12:e0178611.
   PubMed Web of Science ®Google Scholar
• Platz EA, Yegnasubramanian S, Liu JO, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011;1:68–77.
   PubMed Web of Science ®Google Scholar
• Smith TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol. 1985;5:43A–50A.
   PubMed Web of Science ®Google Scholar
• Eade E, Cooper R, Mitchell AR. Digoxin - time to take the gloves off? Int J Cardiol. 2013;164:365–367.
   PubMed Web of Science ®Google Scholar
• Pan L, Zhang Y, Zhao W, et al. The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway. Cancer Chemother Pharmacol. 2017;80:91–100.
   PubMed Web of Science ®Google Scholar
• Hong DS, Henary H, Falchook GS, et al. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014;32:1204–1212.
   PubMed Web of Science ®Google Scholar
• Mekhail T, Kaur H, Ganapathi R, et al. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs. 2006;24:423–427.
   PubMed Web of Science ®Google Scholar
• Garcia DG, Amorim LM, de Castro Faria MV, et al. The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor. Mol Cell Biochem. 2010;345:29–34.
   PubMed Web of Science ®Google Scholar
• Garcia DG, de Castro-Faria-Neto HC, da Silva CI, et al. Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol. Mol Cancer. 2015;14:105.
   PubMed Web of Science ®Google Scholar
• Cho HY, Wang W, Jhaveri N, et al. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 2012;11:2462–2472.
   PubMed Web of Science ®Google Scholar
• Da Fonseca CO, Masini M, Futuro D, et al. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg Neurol. 2006;66:611–615.
   PubMedGoogle Scholar
• Da Fonseca CO, Simão M, Lins IR, et al. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol. 2011;137:287–293.
   PubMed Web of Science ®Google Scholar
• DA Fonseca CO, Teixeira RM, Silva JC, et al. Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation. Anticancer Res. 2013;33:5625–5631.
   PubMed Web of Science ®Google Scholar
• Da Fonseca CO, Khandelia H, Salazar MD, et al. Perillyl alcohol: dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas. Surg Neurol Int. 2016;7:1.
   PubMedGoogle Scholar
• Moreno Y, Banuls L, Katz A, et al. Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase. Mol Cancer. 2013;12:33.
   PubMed Web of Science ®Google Scholar